European Journal of Cancer
Volume 41, Issue 14 , Pages 2093-2101 , September 2005

Multivariate prognostic evaluation of the mitotic activity index and fibrotic focus in node-negative invasive breast cancers

  • Jan P.A. Baak

      Affiliations

    • Department of Pathology, Stavanger University Hospital, Armauer Hansensveg 20, P.O. Box 8100, 4068 Stavanger, Norway
    • The Gade Institute, University of Bergen, Norway
    • Free University Medical Centre, Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +47 51 519534; fax: +47 51 519910.
    • ,
  • Cecile G.A. Colpaert

      Affiliations

    • University Hospital, Antwerp, Belgium
    • ,
  • Paul J. van Diest

      Affiliations

    • University Medical Center, Utrecht, The Netherlands
    • ,
  • Emiel Janssen

      Affiliations

    • Department of Pathology, Stavanger University Hospital, Armauer Hansensveg 20, P.O. Box 8100, 4068 Stavanger, Norway
    • ,
  • Bianca van Diermen

      Affiliations

    • Department of Pathology, Stavanger University Hospital, Armauer Hansensveg 20, P.O. Box 8100, 4068 Stavanger, Norway
    • ,
  • Eliza Albernaz

      Affiliations

    • Department of Pathology, Stavanger University Hospital, Armauer Hansensveg 20, P.O. Box 8100, 4068 Stavanger, Norway
    • ,
  • Peter B. Vermeulen

      Affiliations

    • University Hospital, Antwerp, Belgium
    • ,
  • Eric A. Van Marck

      Affiliations

    • University Hospital, Antwerp, Belgium

Received 28 January 2005 ,Revised 9 March 2005 ,Accepted 30 March 2005.

References 

  1. US National Cancer Institute clinical alert from the National Cancer Institute. Breast Cancer Res Treat 1988, 12, 3–5.
  2. Hébert-Croteau N, Brisson J, Latreille J, et al. Time trends in systemic adjuvant treatment for node-negative breast cancer. J Clin Oncol. 1999;17:1458–1464
  3. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh International Conference on adjuvant therapy of primary breast cancer. J Clin Oncol. 2001;19:3817–3827
  4. European Commission Group on Breast Screening Pathology Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas. Virch Arch 1999, 434, 3–10.
  5. Silvestrini R, Daidone MG, Di Fronzo G. Prognostic implication of labeling index versus oestrogen receptors and tumour size in node-negative breast cancer. Breast Cancer Res Treat. 1986;7:161–169
  6. Amadori D, Nanni O, Marangolo M, et al. Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study. J Clin Oncol. 2000;18:3125–3134
  7. Meyer JS, Friedman E, McCrate MM, et al. Prediction of early course of breast carcinoma by thymidine labeling. Cancer. 1983;51:1879–1886
  8. Sigurdsson H, Baldetorp B, Borg A, et al. Indicators of prognosis in node-negative breast cancer. N Engl J Med. 1990;322:1045–1053
  9. Bergers E, van Diest PJ, Baak JPA. Cell cycle analysis of 932 flow cytometric DNA histograms of fresh frozen breast carcinoma material. Correlations between flow cytometric, clinical and pathologic variables. MMMCP Collaborative Group. Cancer. 1996;77:2258–2266
  10. Bergers E, van Diest PJ, Baak JPA. Prognostic implications of different cell cycle analysis models of flow cytometric DNA histograms of 1301 breast cancer patients: results from the Multicenter Morphometric Mammary Carcinoma Project. Int J Cancer. 1997;74:260–269
  11. Silvestrini R, Daidone MG, Luisi A, et al. Cell proliferation in 3800 node-negative breast cancers: consistency over time of biological and clinical information provided by 3H-thymidine labelling index. Int J Cancer. 1997;74:122–127
  12. Volpi A, De Paola F, Nanni O, et al. Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study. Breast Cancer Res Treat. 2000;63:181–192
  13. Michels JJ, Marnay J, Delozier T, et al. Proliferative activity in primary breast carcinomas is a salient prognostic factor. Cancer. 2004;100:455–464
  14. Groenendijk RP, Bult P, Noppen CM, et al. Mitotic activity index in interval breast cancers. Eur J Surg Oncol. 2003;29:29–31
  15. Daidone MG, Silvestrini R. Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer. J Natl Cancer Inst Monogr. 2001;30:27–35
  16. Volpi A, Nanni O, De Paola F, et al. HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer. J Clin Oncol. 2003;21:2708–2712
  17. Baak JP, Van Dop H, Kurver PH, et al. The value of morphometry to classic prognosticators in breast cancer. Cancer. 1985;56:374–382
  18. Van Diest PJ, Baak JP, Matze-Cok P, et al. Reproducibility of mitosis counting in 2469 breast cancer specimens: results from the multicenter morphometric mammary carcinoma project. Hum Pathol. 1992;23:603–607
  19. Lehr HA, Hansen DA, Kussick S, et al. Assessment of proliferative activity in breast cancer: MIB-1 immunohistochemistry versus mitotic figure count. Hum Pathol. 1999;30:1314–1320
  20. Van der Linden JC, Baak JP, Lindeman J, et al. Prospective evaluation of prognostic value of morphometry in patients with primary breast cancer. J Clin Pathol. 1987;40:302–306
  21. Van Diest PJ, Baak JP. The morphometric prognostic index is the strongest prognosticator in premenopausal lymph node-negative and lymph node-positive breast cancer patients. Hum Pathol. 1991;22:326–330
  22. Baak JP, van Diest PJ, Benraadt T, et al. The multi-center morphometric mammary carcinoma project (MMMCP) in The Netherlands: value of morphometrically assessed proliferation and differentiation. J Cell Biochem. 1993;(Suppl. 17G):220–225
  23. Jannink I, van Diest PJ, Baak JP. Comparison of the prognostic value of four methods to assess mitotic activity in 186 invasive breast cancer patients: classical and random mitotic activity assessments with correction for volume percentage of epithelium. Hum Pathol. 1995;26:1086–1092
  24. De Jong JS, van Diest PJ, Baak JPA. Hot spot microvessel density and the mitotic activity index are strong additional prognostic indicators in invasive breast cancer. Histopathology. 2000;36:306–321
  25. Bergers E, Jannink I, van Diest PJ, et al. The influence of fixation delay on mitotic activity and flow cytometric cell cycle variables. Hum Pathol. 1997;28:95–100
  26. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403–410
  27. Hasebe T, Sasaki S, Imoto S, et al. Highly proliferative fibroblasts forming fibrotic focus govern metastasis of invasive ductal carcinoma of the breast. Mod Pathol. 2001;14:325–337
  28. Jitsuiki Y, Hasebe T, Tsuda H, et al. Optimizing microvessel counts according to tumour zone in invasive ductal carcinoma of the breast. Mod Pathol. 1999;12:492–498
  29. Colpaert CG, Vermeulen PB, van Beest P. Intratumoural hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph-node negative breast cancer patients. Histopathology. 2001;39:1–10
  30. Medri L, Nanni O, Volpi A, et al. Tumour microvessel density and prognosis in node-negative breast cancer. Int J Cancer. 2000;89:74–80
  31. Hasebe T, Sasaki S, Imoto S, et al. Proliferative activity of intratumoural fibroblasts is closely correlated with lymph node and distant organ metastases of invasive ductal carcinoma of the breast. Am J Pathol. 2000;156:1701–1710
  32. Hasebe T, Tsuda H, Tsubono Y, et al. Fibrotic focus in invasive ductal carcinoma of the breast: a histopathological prognostic parameter for tumour recurrence and tumour death within 3 years after the initial operation. Jpn J Cancer Res. 1997;89:590–599
  33. Hasebe T, Tsuda H, Hirohashi S, et al. Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res Treat. 1998;49:195–208
  34. Hasebe T, Tsuda H, Hirohashi S. Fibrotic focus in invasive ductal carcinoma: an indicator of high tumour aggressiveness. Jpn J Cancer Res. 1996;87:385–394
  35. Hasebe T, Sasaki S, Imoto S, et al. Prognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational study. Mod Pathol. 2002;15:502–516
  36. Colpaert CG, Vermeulen PB, Jeuris W. Early distant relapse in ‘node-negative’ breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour. J Pathol. 2001;193:442–449
  37. Baak JP, van Diest PJ, Ariens AT, et al. The multicenter morphometric mammary carcinoma project (MMMCP). A nationwide prospective study on reproducibility and prognostic power of routine quantitative assessment in The Netherlands. Pathol Res Pract. 1989;185:664–670
  38. Voogd AC, Louwman WJ, Coebergh JW, et al. Impact of the new guidelines for adjuvant systemic treatment of breast cancer at hospital level. Ned Tijdschr Geneeskd. 2000;144:1572–1574
  39. Rutgers EJ, Nortier JW, Tuut MK, et al. Dutch Institute for Healthcare Improvement Guideline, Treatment of breast cancer. Ned Tijdschr Geneeskd. 2002;146:2144–2151
  40. Azzopardi JG, Chepick OF, Hartman WH. The World Health Organisation histological typing of breast tumours – second edition. Am J Clin Pathol. 1982;78:806–816
  41. Volpi A, Bacci F, Paradiso A, et al. Prognostic relevance of histological grade and its components in node-negative breast cancer patients. Mod Pathol. 2004;17:1038–1044
  42. Baak JPA, van Diest PJ, Voorhorst FJ, et al. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node–negative breast cancer patients younger than 55 years. J Clin Oncol. 2005;23:5993–6001
  43. Isola JJ, Kallioniemi OP, Chu LW, et al. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol. 1995;147:905–911
  44. Janssen EA, Baak JP, Guervos MA, et al. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor. J Pathol. 2003;201:555–561
  45. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumour-associated carbonic anhydrases. Cancer Res. 2000;60:7075–7083
  46. Colpaert CG, Vermeulen PB, Fox SB, et al. The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Res Treat. 2003;81:137–147
  47. Harris AL. Hypoxia – a key regulatory factor in tumour growth. Nature Rev. 2002;2:38–47
  48. Bissell MJ, Radisky D. Putting tumours in context. Nature Rev. 2001;1:46–54
  49. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999;341:738–746
  50. Forsythe JA, Jiang BH, Iyer NV. Activation of vascular endothelial growth factor gene-transcription by hypoxia-inducible factor-1. Mol Cell Biol. 1996;16:4604–4613
  51. Vermeulen PB, Gasparini G, Fox SB, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid tumours. Eur J Cancer. 2002;38:1564–1579
  52. Vermeulen PB, Verhoeven D, Hubens G, et al. Microvessel density, endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas. Ann Oncol. 1995;6:59–64
  53. Belien JAM, Van Diest PJ, Baak JPA. Relationships between vascularization and proliferation in invasive breast cancer. J Pathol. 1999;189:309–318
  54. Vermeulen PB, Dirix LY, Libura J, et al. Correlation of the fractions of proliferating tumour and endothelial cells in breast and colorectal adenocarcinoma is independent of tumour histiotype and microvessel density. Microvasc Res. 1997;54:88–92
  55. Fox SB, Gatter KC, Bicknell R. Relationship of endothelial cell proliferation to tumour vascularity in human breast cancer. Cancer Res. 1993;53:4161–4163
  56. Vartanian RK, Weidner N. Correlation of intratumoural endothelial cell proliferation with microvessel density (tumour angiogenesis) and tumour cell proliferation in breast carcinoma. Am J Pathol. 1994;144:1188–1194
  57. Holmgren L, O’Reilly MS, Folkman J. (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1:149–153
  58. van Diest PJ, van der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol. 2004;57:675–681

PII: S0959-8049(05)00559-9

doi: 10.1016/j.ejca.2005.03.038

European Journal of Cancer
Volume 41, Issue 14 , Pages 2093-2101 , September 2005

Article Tools

* Image Usage & Resolution